Skincare company Galderma keeps 2025 outlook, shrugs off U.S. tariff uncertainty
Published by Global Banking and Finance Review
Posted on April 24, 2025
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on April 24, 2025
ZURICH (Reuters) -Swiss skincare company Galderma on Thursday said its sales rose by 8.3% on the year to $1.13 billion during the first quarter and signalled confidence about its prospects for the rest of 2025 despite ongoing uncertainty over U.S. tariffs.
Chief Executive Officer Flemming Ornskov told Reuters the company was sticking its outlook for 2025 as it rolls out new products and pursues increased market share, stressing that Galderma was "totally committed to the U.S."
"The vast majority of our portfolio is not affected by these tariffs right now," Ornskov said, noting that only nine percent of the firm's total sales were impacted by import duties.
"The way we want to manage this situation is to focus on commercial execution, volume, market share gain," he added.
Galderma, which launched on the Swiss stock exchange in March 2024, saw its shares gaining 8.5% in early trading after the results.
Bank Vontobel analyst Stefan Schneider said Galderma's results were positive.
"Over-delivery of 1Q25 sales allows the company to increasingly de-risk and confirm its FY25 guidance despite some further tariff impact in some consumer product categories," he said.
(Writing by Dave Graham, editing by John Revill)